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membranous nephropathy
JAMES V. D0NADJ0, Jr., KEITH E. HOLLEY, CARL F. ANDERSON and WILLIAM F. TAYLOR
Division of Nephrology and Internal Medicine and the Department of Medical Statistics and Epidemiology, Mayo Clinic and
Mayo Foundation, Rochester, Minnesota
Controlled trial of cyclophosphamide in idiopathic membranous
nephropathy. We evaluated cyclophosphamide treatment in a
controlled prospective study of 22 adult patients with clinically
and histologically defined idiopathic membranous nephropathy.
By random assignment, 11 patients received no drug and 11
patients received cyclophosphamide orally, 1.5 to 2.5 mg/kg/day
(mean, 1.8), for one year. Before treatment, the two groups were
similar in age and sex distributions, duration of illness, blood
pressure, degree of proteinuria, renal function and histologic
staging. After treatment, a downward trend in proteinuria was
noted, with no significant difference in the quantity and rate of
decrease between groups. Renal function (C1. and CPAH) was
stable in all patients, with no difference between groups. On
comparing pretreatment and one-year renal biopsy specimens in
eight patients in each group, regardless of treatment or clinical
outcome, the appearance of the renal lesions remained the same
or progressed in terms of basement membrane thickening and
incorporation of subepithelial deposits, and immunofluorescence
with IgG and C3 remained positive in glomerular capillaries.
Cyclophosphamide dosage was decreased in five patients because
of recurrent leukopenia; no other major toxicity was observed.
Beyond one year of treatment, renal function has decreased in
two of eight patients in the no-drug group and in one of seven
patients in the cyclophosphamide-treated group. We conclude
that treatment with cyclophosphamide for one year did not have
a favorable effect on proteinuria, renal function or morphologic
aspects of the glomerular lesion.
Essai contrôlé du cyclophosphamide dans Ia néphropathie mem-
braneuse idiopathique. Nous avons évalué le traitement par le
cyclophosphamide dans une étude prospective contrôlée de
22 malades adultes atteints de néphropathie membraneuse idio-
pathique cliniquement et anatomiquement définie. Au hasard,
onze malade n'ont recu aucun traitement et onze autres ont eu
du cyclophosphamide par voie orate a raison de 1,5 a 2,5 mg/kg
par jour (1,8 en moyenne) pendant un an. Avant le traitement les
deux groupes étaient semblables en distribution d'age et de sexe,
durée de Ia maladie, pression artérielle, importance de Ia pro-
téinurie, fonction rénale et état histologique. Aprés traitement,
une tendance a Ia diminution de Ia protéinurie a été observée
sans difference significative entre les groupes dans le debit de
protéine ou Ia vitesse de diminution. La fonction rénale (C1, et
CPAH) était stable chez tous les malades, sans difference entre les
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groupes. La comparaison des biopsies avant traitement et aprCs
un an chez huit malades de chaque groupe, indCpendamment du
traitement ou de l'évolution clinique, a montré que les lesions
rénales sont restées les mêmes ou ont progressé, sous Ia forme
d'un épaississement de Ia membrane basale et de l'incorporation
de depots sous-épithéliaux, et que l'immunofluorescence avec
IgO et C3 reste positive dans les capillaires glomérulaires. La
posologie du cyclophosphamide a etC diminuée chez cinq
malades en raison d'une leucopénie rCcidivante; aucune autre
toxicité majeure n'a été observée. Au-delà d'un an de traitement,
Ia fonction rénale a diminuC chez deux des huit malades du
groupe ne recevant pas de mCdicament et chez l'un des sept
malades du groupe traité par le cyclophosphamide. Nous con-
cluons que le traitement par le cyclophosphamide pendant un an
n'a pas eu d'effet favorable sur Ia protCinurie, Ia fonction rCnale
ou les lesions histologiques glomerulaires.
Patients with idiopathic membranous nephropathy,
a form of chronic primary glomerulopathy, have a
variable clinical course [1—5]. Because progressive renal
failure may occur, attempts have been made to alter
the disease course with various immunosuppressive
drugs. The largest experience has been with cortico-
steroids, and these are generally considered to be in-
effective [1, 2, 6, 7] on the basis of retrospective
reviews of large numbers of patients. In a British con-
trolled trial of steroid treatment of adult patients with
nephrotic syndrome, prednisone had no effect on
proteinuria or on the function of kidneys with mem-
branous lesions [8]. In another controlled study of
combined treatment with prednisone and azathioprine
in chronic glomerular disease, a small number of
patients with membranous nephropathy did not bene-
fit from the treatment [9]. Treatment results with
mechlorethamine, chlorambucil, and 6-mercapto-
purine cannot be interpreted because of lack of con-
trolled studies and the paucity of patients treated [10,
11].
Cyclophosphamide has been successfully used in the
treatment of patients with nephrotic syndrome and
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minimal glomerular changes (lipoid nephrosis) [12—
14], especially in children with a relapsing course who
are dependent on steroid treatment [14]. In spite of
these good results, use of cyclophosphamide has been
curtailed because of the potential risks of hemorrhagic
cystitis [15], urinary bladder fibrosis [16] and perma-
nent sterility in both prepubertal and pubertal males
[17—19] and in some females [20]. A preliminary report
[21] has described decreased proteinuria in patients
with membranous nephropathy who were treated with
cyclophosphamide. However, the glomerular lesions
were not precisely defined and the study lacked con-
trols. During the same period, we gave cyclophospha-
mide to several patients with idiopathic membranous
nephropathy and observed substantial decreases in
proteinuria, but we were uncertain if the improvement
was due to the treatment or to the natural course of the
disease.
Because the disease may progress to renal failure,
cyclophosphamide therapy might be effective, and be-
cause it is possible to define the renal lesion morpho-
logically, we designed and herein report a controlled
study of cyclophosphamide treatment of adult
patients with idiopathic membranous nephropathy.
Methods
Patient selection. Patients were accepted in the study
after the diagnosis of idiopathic membranous nephro-
pathy was established by certain clinical and histologic
criteria (no children were considered for study). Clini-
cally, none had systemic lupus erythematosus, diabetes
mellitus, malignancy, known exposure to heavy metals,
congenital or secondary syphilis or renal vein throm-
bosis. Eight patients had renal venography to rule out
renal vein thrombosis, No patient had received prior
cytotoxic drug treatment. Several had received or
were currently receiving prednisone treatment; such
treatment was tapered off and then stopped within
30 days. All patients had either the nephrotic syndrome
or severe proteinuria. A precutaneous renal biopsy was
performed in all patients.
Renal histologic analysis. The histologic criteria for
the diagnosis of membranous nephropathy were a
modification of those of Ehrenreich and Churg [5] and
Rosen [22] and have been reported [1]. These criteria
and staging of the development of the glomerular
lesion were based on a combination of light and
electron microscopic (EM) findings. Briefly, three
stages of development were defined as follows,
1) Early or stage 1 lesion: Capillary walls are irregu-
larly thickened; many appear normal. There are small
electron-dense deposits, frequently arranged in clusters
in a subepithelial location and on the surface of the
basement membrane. There are scattered areas of sub-
epithelial extensions of the basement membrane
appearing as silver-positive projections ("spikes") on
sections stained by the Jones silver methenamine
method.
2) Well-developed or stage 2 lesion: There is more
uniform thickening of the capillary walls. Deposits are
distributed over all of the capillaries and some are
located within the basement membrane. Basement
membrane "spikes" are prominent.
3) Advanced or stage 3 lesion: Capillary loops are
very thick; many deposits are incorporated in the
basement membrane with loss of electron density,
giving the basement membrane a "moth-eaten"
appearance.
There often is overlap in staging and variation from
glomerulus to glomerulus in a given biopsy specimen
with changes characteristic of each category (especially
a mixture of stage 2 and stage 3 changes). Also, in each
of these stages there may be focal mesangial thicken-
ing, capsular adhesions, crescents and glomerular
sclerosis.
One of us (K. E. H.) initially staged all of the biop-
sies; in preparing the material for publication, two of us
(K. E. H. and J. V. D.) reviewed the slides and electron
micrographs (EM). In three instances, the original clas-
sification as stage 1 was changed to stage 2 on review.
The final histologic classifications are presented here.
Treatment randomization and treatment protocol.
After fulfilling clinical and histologic criteria for a
diagnosis of idiopathic membranous nephropathy,
each patient was advised of the nature of the study; of
the attendant risks, side-effects and expectations of
treatment; and of the follow-up requirements. On
agreeing to participate, the patient was placed in one
of two treatment groups by random assignment. No
bias in assigning patients to treatment was possible be-
cause only after a patient was deemed eligible was the
treatment ascertained by referral to a list created from
a table of random numbers (by W. F. T.). The table
was maintained by the renal pathologist (K. E. H.) and
was not seen by the clinicians (J. V. D. and C. F. A.).
After reviewing a patient's renal biopsy specimen by
light microscopy and establishing a diagnosis of mem-
branous nephropathy, and without further knowledge
of the clinical details of the case, the pathologist noti-
fied one of the clinicians who then discussed the nature
of the study with the patient. To that point, neither
patient nor clinician knew what treatment was going to
be given. After the patient agreed to enter study, the
clinician then called the pathologist who assigned the
patient to either cyclophosphamide or no-drug treat-
ment. No placebo was used, and the patients who re-
ceived cyclophosphamide were fully informed of the
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side-effects and precautions to be taken during the
treatment period.
One treatment group received cyclophosphamide,
1.5 to 2.5 mg/kg/day by oral administration; the other
group received no drug. Treatment was planned for
one year with detailed follow-up at four-month inter-
vats for all patients. For those patients receiving cyclo-
phosphamide, leukocyte (total and differential) and
platelet counts were made weekly during the first
month of treatment. If these counts remained satis-
factory, after the first month they were rechecked at
intervals of three to four weeks throughout the course
of treatment. If the leukocyte count was less than
3,000/mm3 or if the platelet count was less than
80,000/mm3, the drug was stopped for a minimum of
seven days. When the counts increased to above these
limits, treatment was started again at one-half the
previous dose and then increased to the initial dose
level if possible. Patients were instructed to drink
fluids liberally to avoid the complication of hemorrha-
gic cystitis [23, 24]. Most patients took the drug once
a day with their largest meal. All patients were advised
to practice contraception during cyclophosphamide
treatment. The three women of childbearing age (ages
26, 32 and 40 yr) in the study were not pregnant (two
received no drug and one received cyclophosphamide).
Attention was paid to extracellular fluid volume and
blood pressure in all patients, and, when appropriate,
antihypertensive and diuretic agents were used. Since
nearly all patients had the nephrotic syndrome with
edema, all were initially instructed in and advised to
follow sodium-controlled diets (40 to 90 mEq of
sodium/day).
Follow-up observations. Initially and at four-month
intervals, patients received physical examinations and
the following laboratory tests: urinalysis including
urine sediment examination (first morning specimen);
hemoglobin concentration, hematocrit value, and ery-
throcyte, total and differential leukocyte and platelet
counts; serum protein electrophoresis; serum chole-
sterol and creatinine concentrations; total serum com-
plement (initial examination only); 24-hr urinary total
protein (paired determinations on separate 24-hr
collections made two weeks apart); and standard in-
fusion clearances of inulin (C111) and p-aminohippurate
(CFAH). The renal clearances were performed in the
Renal and Electrolyte Laboratory. All other labora-
tory tests were performed by standard techniques in
the clinical laboratories of the Mayo Clinic.
Twenty-two initial renal biopsy specimens and 16
12-month-treatment biopsy specimens were processed
by previously described techniques [1, 25]. All 38 speci-
mens were examined by light microscopy and EM.
Tissue for immunofluorescence study was adequate for
examination in 18 of the 22 cases and included follow-
up biopsy specimens in 11 cases (total of 29 biopsies).
Statistical methods. Statistical methods used were
paired t test analysis of differences in proteinuria, C111
and CPAH within each treatment group and nonpaired
t test analysis and 95% confidence intervals (CI) of
average differences between the groups.
Results
From May 1971 to June 1973, 22 adult patients
entered the study (11 assigned to each treatment
group). Ten patients in the no-drug group and nine
patients in the cyclophosphamide-treated group had
complete measurements during the 12-month period.
In two patients in the cyclophosphamide-treated
group, the drug was stopped after eight months, on the
advice of the clinicians, when data analysis to that
point revealed no treatment benefit either to these
patients or to the 19 patients who had completed the
study. One patient in the no-drug group was dropped
from the study because she had a dramatic change in
her clinical, renal function and morphologic course at
five months of treatment, and we could no longer con-
sider her to have purely membranous nephropathy
(see Appendix).
Pretreatment observations. Table 1 shows the cate-
gories and distribution of initial clinicopathologic data
in the 22 patients. Sex ratios and age ranges and means
were comparable. The duration of illness, defined as
the time between first discovery of proteinuria or
edema and entry into the study, was also comparable.
Hypertension, defined as several blood pressure
measurements exceeding 150/100 mm Hg, was present
in two patients in each group. Three patients in the
cyclophosphamide-treated group and four in the no-
drug group had had prior steroid treatment; none had
received cytotoxic drugs. Ranges and means of pro-
teinuria and renal function were similar in each group.
There was an equal distribution of renal lesions by
morphologic staging in each group. Serum concentra-
tions of creatinine, albumin, total protein, cholesterol
and total complement also were comparable.
Proteinuria. There was a downward trend in pro-
teinuria in each treatment group (Fig. 1). The average
decrease in protein excretion (end-of-treatment value
minus pretreatment value) was 4.7 g/24 hr (SD, 3.2) in
the cyclophosphamide-treated group (P <0.01) and
2.6 g/24 hr (SD, 3.5) in the no-drug group (P<0.05).
Obviously, the groups did not differ much (2.1 g/24 hr),
and this difference was not statistically significant
(P0.2; 95% CI, —1.1 to 5.3).
Nine patients in each treatment group had the ne-
phrotic syndrome on initial evaluation (urinary protein
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Table 1. Pretreatment observations on patients with idiopathic
membranous nephropathy
Observation Treatment
Cyclophos-
phamide
No drug
Patients, N
Men
Women
11
9
2
11
8
3
Age: range and mean, yr
Men
Women
25—74 (41,1)
40—59 (49.5)
34—69 (47.6)
26—65 (41.0)
Duration of illness: range and
median, months 3—27 (7) 2—108 (5)
Hypertension, N
(BP>150/lOOmmHg)
Prior steroid treatment, N
2
3
2
4
Proteinuria: range and mean,
g/24 hr 2—16.6 (7.8) 2—12.1 (7.6)
Renal clearances, ml/min/1.73 m2
Cth
Range
Mean
44—117
75
33—112
80.6
CPAH
Range
Mean
356—651
506
286—816
504
Renal biopsy, N
Early (stage 1)
Well-developed (stage 2)
Advanced (stage 3)
3
7
1
2
8
1
Serum chemistry
Creatinine: range and mean,
mg/100 ml
Albumin: range and mean,
g/100 ml
Total protein: range and
mean, g/100 ml
Cholesterol: range and
mean, mg/100 ml
Serum total complement:
range and mean, ua
0.8—1.9 (1.2)
1.9—3.4 (2.7)
4.2—6.3 (5.4)
235—440 (393)
53—90 (73)
0.8—2.2 (1.1)
1.6—3.7 (2.3)
4.3—5.9 (5.1)
217—490 (357)
46—86 (67)
Normal, 41 to 90 U.
excretion of 3.5 g/24 hr or greater, combined with
urinary excretion of lipids). Two patients in each group
presented with non-nephrotic proteinuria, but all had
previously been documented to have the nephrotic
syndrome. After treatment, six patients (four in the
cyclophosphamide-treated group and two in the no-
drug group) had partial remission of the nephrotic
syndrome (urinary protein excretion less than 2 g/
24 hr). In addition, these patients no longer had
edema and, as a group, had an average increase in
serum albumin (1.1 g/l00 ml) and total protein
(0.6 g/l00 ml) concentrations and an average decrease
in serum cholesterol concentration (160 mg/l00 ml).
Renal function. Glomerular filtration rate remained
essentially stable in both groups, as indicated by indivi-
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Fig. 1. Urinary protein excretion of each patient in the two treat-
ment groups before treatment (time 0) and at each follow-up. Each
point represents mean of two determinations made within a two-
week period. Individual patient measurements show a variable
pattern, but group means (———) showa downward trend. *Patient
who had a dramatic change in her clinical course at five months.
dual C values and means (Fig. 2). C1,, increased by an
average of 8 ml/min/1 .73 m2 in the cyclophosphamide-
treated group and by 2 mi/mm/I .73 m2 in the no-drug
group; this difference is not statistically significant
(Pii0.2; 95% CI, —3.7 to 16.7). Similar data were
obtained for renal plasma flow: CPAH increased by an
average of 23 and 22 mI/mm/I .73 m2, respectively
(P0.9; 95% CI, —63.8 to 64.6).
Renal morphology. As indicated in Table 1, there was
an even distribution of lesions by staging in the 22 ini-
tial biopsy specimens of the two groups. Biopsies were
performed both before and after treatment in eight
patients in each group (Table 2). The appearance of
the renal lesions remained the same or progressed in
terms of glomerular basement membrane thickening
a
U
4 2
Fig. 2. Glomerular filtration rate (GFR), measured by C,,,, of each
patient in the two treatment groups before treatment (time 0) and
at each follow-up. GFR remained stable throughout the
12months of observation in both groups (— — — = group means).
*patjent who had a dramatic change in her clinical course at five
months.
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Table 2. Renal biopsy findings before and after treatment and
clinical outcome
Patient
No.
Stage° of renal lesion Clinical
outcom&'
Before At 12 months
drug
Cyclophosphamide
1 2 3 PNS
2 2 3 PNS
3 1 2 PP
4 3 3 PNS
5 2 2 PNS
6 1 2 PRNS
7 2 3 PNS
8 2 2 PRNS
No drug
1 2 3 PP
2 2 3 PNS
3 2 3 PNS
4 1 2 PRNS
5 1 2 PP
6 2 2 PNS
7 2 2 PP
8 2 20 See Appendix
Staging of lesions: 1 = early; 2= well-developed; 3 = advanced.b Persistent nephrotic syndrome (PNS)= proteinuria>3.5 g/24hr
and lipiduria; persistent proteinuria (PP) >2 g/24 hr; partial re-
mission of nephrotic syndrome (PRNS) =proteinuria 0.2 to
2 g124 hr.
° Renal biopsy at five months, after rapid deterioration of renal
function and hematuria, showed extensive extracapillary pro-
liferation superimposed on a well-developed membranous lesion.
and incorporation of subepithelial deposits with any of
the types of clinical outcome. By light and EM assess-
ments, no lesion regressed. In the cyclophosphamide-
treated group, three remained in the same stage and
five progressed to the next stage; in the no-drug group,
two remained in the same stage and five progressed to
the next. In patient 8 of the no-drug group, a renal
biopsy specimen at five months showed extensive
extracapillary proliferation superimposed on a well-
developed membranous lesion, the type of lesion pre-
sent in her initial biopsy (this case is described in the
Appendix). Morphologic examples of each of the
stages of the lesion are shown in Figs. 3 through 5.
On immunofluorescence study, IgG was present in
all 29 biopsy specimens. The pattern varied from
smooth and finely granular staining to diffuse and
coarsely granular staining of the glomerular capillary
walls. C3 was positive in all but two biopsy specimens
and the staining patterns were similar to IgG but
fluorescence usually was less intense. Fibrinogen was
present in six biopsy specimens as an irregular,
granular staining pattern of the capillaries. 1gM was
found in 5 of 11 specimens in an irregular, coarsely
granular pattern in some but not all glomeruli; four
Fig. 3. Electron and light photomicrographs of early membranous
glomerulopathy (stage 1). Inset, No thickening of peripheral
capillary walls. EP= epithelial cell cytoplasm; d= subepithelial
deposits; BM = basement membrane. Arrows indicate early base-
ment membrane extensions between deposits. (Original magni-
fication, x 10,000. Inset, periodic acid-Schiff; x 400.)
Fig. 4. Renal biopsy showing well-developed membranous nephro-
pathy (stage 2). a, Diffuse thickening of the capillary walls due to
subepithelial deposits (arrow) (Mallory-Heidenhain; x 1,000).
b, Diffuse subepithelial projections (arrow) of basement mem-
brane "spikes" (methenamine silver; x 1,000). c, Diffuse
granular staining along capillary wall (fluorescein-conjugated
antihuman IgG; x 540), d, Electron micrograph showing sub-
epithelial deposits (d), beginning incorporation of deposits into
basement membrane (d1), spikes (s), basement membrane (bm),
capillary lumen (c) and fused epithelial foot processes (EP) (re-
duced from x 13,000).
_ae_..__, —4ti;1'
4 Ia.,
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lesions were stage 2 and one was stage 3. IgA was
located in the glomerular capillaries in a coarsely
granular pattern in 2 of 11 specimens. In the second
biopsy of 11 pairs, IgG was of the same intensity in 7,
less in 3 and more in 1 pair; C3 was the same in 5, less
in 4 and more in 2 pairs. Immunofluorescence with
IgG and C3 did not become negative in any of the
second biopsies.
Treatment effects. In the cyclophosphamide-treated
group, the initial dose was 1.5 to 2.5 mg/kg/day (mean,
1.8) and the cumulative dose in the nine patients who
completed 12 months of study ranged from 310 to
665 mg/kg (Table 3). The dosage had to be decreased
during treatment in five patients and stopped for one-
to two-week periods in three of these patients because
of persistently recurring leukopenia. There was partial
alopecia in three patients and transient nausea in one
patient; neither symptom required cessation of treat-
ment. There was no recognized thrombocytopenia,
hemorrhagic cystitis, opportunistic pulmonary infec-
tion or hepatotoxicity. Gonadal function was not
tested in any patient.
In the no-drug group, no leukopenia was observed
and none of the patients had any of the above symp-
toms or signs.
Follow-up beyond one year. Eight patients in the no-
drug group and seven in the cyclophosphamide-treated
Fig. 5. Advanced glomerular lesion of
membranous glomerulonephropatliy
(stage 3). Extensive thickening of
capillary wall with incorporation of
subepithelial deposits (d) into the
basement membrane (BM). Note
areas of decreased electron density
(arrows). Ep =epithelial cell cyto-
plasm; CL= capillary lumen (electron
micrograph; reduced from x 8,000).
Inset, Diffuse thickening of capillary
walls with decrease in diameter of
capillaries and increase in mesangial
matrix (periodic acid-Schiff; x 400).
group have been followed for an average of one year
beyond the one year of treatment. In the cyclophos-
phamide-treated group, one patient has decreasing
renal function; in the no-drug group, two patients
have decreasing renal function (decrease in Ci, of 25%
or more compared with the one-year value). No
patient has developed renal failure. Two patients in the
no-drug group and three in the cyclophosphamide-
treated group have remained in partial nephrotic re-
mission; the rest of the patients are persistently
nephrotic or proteinuric with stable renal function.
Discussion
In this prospective controlled study of patients with
idiopathic membranous nephropathy, treatment with
cyclophosphamide did not favorably affect proteinuria,
renal function or morphology of the glomerular lesion.
The general downward trend in proteinuria was con-
tributed to mainly by the substantial improvement
noted in some patients—27% of all patients showed a
decrease of proteinuria to less than 2 g/24 hr. This was
accompanied by improvement in other manifestations
of the nephrotic syndrome, such as edema and serum
proteins and lipids. An incidence of 27% for partial
nephrotic remission is comparable to that observed in
long-term follow-up of other patients with idiopathic
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Table 3. Summary of cyclophosphamide treatments
Cyclophosphamide doses
CommentPatient Initial
Period IS Period 2 Penod 3
Cumulative Cumulative Cumulative
No. mg/kg/day mg/day mg/kg mg/day mg/kg mg/day mg/kg
1 2.0 50—100 175 50 265 50 385 Stopped 2 wk in 1;
decr. 1—-3 (leuko-
penia)
2 2.0 150 214 150 454 100 604 Decr. in 3 (leukopenia)
3 2.5 200 300 100 487 100 600 Decr. in 2 and 3 (leu-
kopenia)
4 1.5 100 180 100 450 100 630 None
5 1.5 100 180 100 360 100 540 None
6 1.5 75—100 115 75—125 220 75 310 Stopped 1 wk in 3;
decr. most of 1—÷3
(leukopenia)
7 1.5 100 132 50—100 265 100 495 Stopped 1 wk in 3;
decr. 3 wk in 2 (leu-
kopenia)
8 1.5 100 225 100—150 435 100 615 Incr.3moin2
9 1.75 150 221 150 445 150 665 None
10 2.0 150 240 None
11 2.0 150 240 None
Each period refers to four months of treatment.
membranous nephropathy [1—3, 7]. In all patients,
glomerular filtration rate and renal plasma flow re-
mained essentially stable throughout the 12 months of
observation, so the decrease in protein excretion can-
not be attributed to decreasing renal function.
That the glomerular lesions did not regress in either
group, or in patients who had a substantial decrease in
proteinuria, is not a surprising observation. Com-
plete resolution of basement membrane thickening and
disappearance of subepithelial deposits has been rarely
observed [2, 26]. While it has been shown that early
(stage 1) lesions are generally associated with a more
favorable clinical course, the stage of an individual
glomerular lesion by biopsy criteria and the ultimate
outcome of the patient are not always correlated [1—3].
Franklin, Jennings and Earle [3] pointed out that, in
patients who achieved nephrotic remission, the glomer-
ular deposits were incorporated into the basement
membrane, which was also diffusely thickened, a pro-
cess that is a feature of an advanced lesion (stage 3). In
a previously reported study by ourselves [1] and in the
majority of patients in this study, there was progres-
sion of pathologic staging in patients who either en-
tered partial nephrotic remission or who remained
nephrotic but retained good renal function. In the
clinical setting of nephrotic remission and stable renal
function, these morphologic changes, heretofore con-
sidered advancement of the lesion, may be indicative
of stabilization or healing of the glomerular basement
membrane which becomes less permeable to protein
molecules and maintains filtration.
That treatment should be attempted at all in this
form of chronic glomerulopathy is justified by the
known long-term outcome of patients with idiopathic
membranous nephropathy [1—5, 7]. Progressive renal
disease, manifested by a relatively short course to renal
failure [1—3] or the more usual slowly progressive
course [1—5, 7], is an important feature of the pro-
cess. The nephrotic syndrome is the commonest pre-
senting illness, and persistent severe proteinuria is also
the most frequent course of events [1—5, 7]. Therefore,
it seemed worthwhile to us to attempt a relatively
short trial of treatment in a disease that has a chronic
course, using measurements of protein excretion and
renal function as our best guides to treatment effects.
The experience with cyclophosphamide in minimal-
change glomerulopathy, and our own anecdotal ex-
perience in a few patients with idiopathic membranous
nephropathy, led to our using this drug in this study.
In our controlled study, there exists the possibility
that subtle differences between the two groups might
have been detected if there had been longer treatment
of more patients followed for a longer period. The
clinical significance of any subtle differences that
might emerge has yet to be established, and the desir-
ability of achieving such differences would be deter-
mined by their nature and weighed against the relative
risk of treatment.
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Cyclophosphamide was well tolerated, with few un-
toward side-effects noted. The only major toxicity was
leukopenia that persisted in nearly one-half of the
patients, necessitating a permanent decrease from the
initial dosage. This decrease in dosage has also been
observed by Fries [27], who used cyclophosphamide in
the treatment of connective tissue disorders, in which
patients are predisposed to leukopenia.
It is clear that steroids and the cytotoxic agents,
azathioprine and cyclophosphamide, do not favorably
alter the course of membranous nephropathy. Further-
more, no treatment currently available appears to have
potential benefit to such patients. The best course of
action seems to be to identify properly the glomerular
process in patients with clinical evidence of glomerular
disease. When membranous nephropathy is identified,
and known associated disorders can be excluded, then
attention should be given to the proper management of
the nephrotic state and avoidance of exposing the
patient to drugs that offer only potential harm.
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Appendix
Report ofpatient (no-drug group) droppedfrom study.
A 32-yr-old woman was admitted to the study in
August 1972, after a clinical diagnosis of nephrotic
syndrome and a morphologic diagnosis of a well-
developed lesion of membranous nephropathy. Initial-
ly, her serum creatinine concentration was 0.9mg!
100 ml, C1 and CFAIT were 86 and 816 ml/min/l.73m2,
respectively, and urinary protein excretion was 9.3 and
11.7 g/24 hr. She was placed in the no-drug group.
In January 1973, five months after entering the
study, she had an illness characterized by fever, chills,
malaise, anorexia, myalgias and gross hematuria. She
was hospitalized and found to be severely anemic
(hemoglobin value, 7.3 g/100 ml), and her serum
creatinine concentration reached a peak of 7.4 mg/
100 ml. The urine contained gross blood and numerous
casts including erythrocyte and blood varieties. Urin-
ary protein concentration was 16.5 g/24 hr. Renal vein
thrombosis was excluded as a possible finding by veno-
graphy. A repeat renal biopsy showed generalized and
extensive extracapillary proliferation that appeared to
be superimposed on a well-developed membranous
lesion. There also was mild intracapillary cellular in-
crease and marked swelling of the visceral epithelial
cells. Observations by immunofluorescent microscopy
were consistent with membranous nephropathy in that
there was diffuse, granular staining of the capillary walls
with IgG and C3. By the indirect immunofluorescent
technique [28], anti-GBM antibody (fluorescein-
conjugated goat anti-human IgG, Hyland Labora-
tories, Costa Mesa, CA) was searched for in the
patient's serum but not found.
The patient was treated with prednisone, and one
month later her hematuria had cleared, serum creati-
nine concentration decreased to 1.3 mg/100 ml, and
urinary protein excretion was 17.7 g/24 hr. Over a
three-month period, prednisone administration was
tapered off to discontinuation. One month later, the
patient had recurrent hematuria, her blood pressure
was increased to 210/130 mm Hg, and serum creati-
nine concentration had increased to 3.3 mg/100 ml.
She was again hospitalized for blood pressure control,
and prednisone treatment was reinstituted. Improve-
ment in both blood pressure and renal function
followed, and at the latest follow-up (November 1973),
blood pressure was 130/85 mm Hg, serum creatinine
concentration was 1.1 mg/100 ml, and and CPAH
were 44 and 392 ml/min/l.73 mm2, respectively.
In a similar patient recently presented by Klassen
et a! [29], idiopathic membranous nephropathy was
accompanied by the appearance of pleurisy, sudden
anuria and death while receiving dialysis treatment.
Autopsy showed extensive extra-capillary proliferation
of the kidney, as in the second biopsy specimen in our
patient. In addition, immuno-fluorescent microscopy
and elution antibody studies supported their conten-
tion that the original lesion had evolved into a rapidly
progressive anti-GBM glomerulonephritis.
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